Compare ABCL & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCL | NFJ |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | N/A |
| Metric | ABCL | NFJ |
|---|---|---|
| Price | $5.97 | $15.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.40 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 165.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | ★ 10.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,128,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 160.56 | N/A |
| 52 Week Low | $2.75 | $12.25 |
| 52 Week High | $8.44 | $15.42 |
| Indicator | ABCL | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 54.05 |
| Support Level | $5.23 | $14.89 |
| Resistance Level | $6.79 | $15.20 |
| Average True Range (ATR) | 0.61 | 0.17 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 14.66 | 40.74 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.